Cargando…

Immune-checkpoint inhibitor-associated grade 3 hepatotoxicity managed with enteric-coated budesonide monotherapy: A case report

RATIONALE: The introduction of immune-checkpoint inhibitors (ICPI) in recent years has changed the natural course of many neoplasms. However, patients receiving these medications may present immune-mediated adverse events; management includes temporary or permanent cessation of treatment and cortico...

Descripción completa

Detalles Bibliográficos
Autores principales:	Eleftheriotis, Gerasimos, Skopelitis, Elias
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9351916/ https://www.ncbi.nlm.nih.gov/pubmed/35945730 http://dx.doi.org/10.1097/MD.0000000000029473

Ejemplares similares

Concurrence of cat-scratch disease and paradoxical tuberculosis-IRIS lymphadenopathy: a case report
por: Eleftheriotis, Gerasimos, et al.
Publicado: (2022)

Open-Capsule Budesonide for the Treatment of Isolated Immune Checkpoint Inhibitor-Induced Enteritis
por: Hussain, Nadeen, et al.
Publicado: (2022)

Budesonide treatment for microscopic colitis from immune checkpoint inhibitors
por: Hughes, Michael S., et al.
Publicado: (2019)

Checkpoint Inhibitors and Hepatotoxicity
por: Malnick, Stephen D. H., et al.
Publicado: (2021)

Immune checkpoint inhibitor-related hepatotoxicity: A review
por: Remash, Devika, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors Induced Hepatotoxicity; Gastroenterologists’ Perspectives
por: Farshidpour, Maham, et al.
Publicado: (2022)

Hepatotoxicity of immune checkpoint inhibitors: What is Currently Known
por: Zheng, Caiyun, et al.
Publicado: (2023)

Overlapping Hepatotoxicity and Colitis Associated with Immune Checkpoint Inhibitors
por: Malik, Alexander, et al.
Publicado: (2023)

Formulation and evaluation of sustained release enteric-coated pellets of budesonide for intestinal delivery
por: Raval, Mihir K, et al.
Publicado: (2013)

Hepatotoxicity in Patients with Hepatocellular Carcinoma on Treatment with Immune Checkpoint Inhibitors
por: Personeni, Nicola, et al.
Publicado: (2021)

The Current status of steroid-refractory immune-checkpoint-inhibitor-related hepatotoxicity
por: Xing, Hui, et al.
Publicado: (2023)

Checkpoint inhibitor-induced hepatotoxicity: Role of liver biopsy and management approach
por: Bessone, Fernando, et al.
Publicado: (2022)

Emerging Role of Vedolizumab in Managing Refractory Immune Checkpoint Inhibitor–Induced Enteritis
por: Diana, Pietro, et al.
Publicado: (2018)

Hepatotoxicity in immune checkpoint inhibitors: A pharmacovigilance study from 2014–2021
por: Xu, Ze, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: Monotherapies and Combined Therapies
por: Ouyang, Tao, et al.
Publicado: (2022)

Managing cardiotoxicity associated with immune checkpoint inhibitors
por: Upadhrasta, Sireesha, et al.
Publicado: (2019)

Immune checkpoint inhibitor‐induced enteritis assessed using capsule endoscopy
por: Otagiri, Shinsuke, et al.
Publicado: (2020)

Immune checkpoint inhibitor therapy associated enteritis mimicking celiac disease
por: Khandakar, Binny, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors as Monotherapy or Within a Combinatorial Strategy in Advanced Hepatocellular Carcinoma
por: Guardascione, Michela, et al.
Publicado: (2020)

Immune checkpoint inhibitor monotherapy is associated with less cardiac toxicity than combination therapy
por: Cone, Eugene B., et al.
Publicado: (2022)

Real-World Outcomes and Clinical Predictors of Immune Checkpoint Inhibitor Monotherapy in Advanced Lung Cancer
por: Zhang, Shijia, et al.
Publicado: (2021)

Liver metastasis affects progression pattern during immune checkpoint inhibitors monotherapy in gastric cancer
por: Motoo, Iori, et al.
Publicado: (2023)

Dual checkpoint inhibitor-associated eosinophilic enteritis
por: Yang, J., et al.
Publicado: (2019)

Evaluation of liver enzyme elevations and hepatotoxicity in patients treated with checkpoint inhibitor immunotherapy
por: Cunningham, Morven, et al.
Publicado: (2021)

Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer with ALK Rearrangement
por: Oya, Yuko, et al.
Publicado: (2020)

Efficacy and safety of immune checkpoint inhibitor monotherapy in elderly patients with non‐small cell lung cancer
por: Chikaishi, Yasuhiro, et al.
Publicado: (2021)

PD-1 Immune Checkpoint Inhibitor Therapy Malignant Tumor Based on Monotherapy and Combined Treatment Research
por: Zhang, Yu, et al.
Publicado: (2021)

Management of Immune Checkpoint Inhibitor Toxicities
por: Durrechou, Quentin, et al.
Publicado: (2020)

Immune checkpoint blockade can synergize with radiation therapy, even in tumors resistant to checkpoint monotherapy
por: Dörrie, Jan
Publicado: (2016)

Enteric Budesonide in Transplant and Native IgA Nephropathy: Real-World Clinical Practice
por: Lopez-Martinez, Marina, et al.
Publicado: (2022)

Immune checkpoint inhibitor (ICI) combination therapy compared to monotherapy in advanced solid cancer: A systematic review
por: Ma, Xiaoting, et al.
Publicado: (2021)

Early mortality factors in immune checkpoint inhibitor monotherapy for advanced or metastatic non-small cell lung cancer
por: Takeuchi, Eiji, et al.
Publicado: (2022)

Challenges and knowledge gaps with immune checkpoint inhibitors monotherapy in the management of patients with non-small-cell lung cancer: a survey of oncologist perceptions
por: Castelo-Branco, L., et al.
Publicado: (2023)

Immune Checkpoint Inhibitors in the Management of Urothelial Carcinoma
por: Patel, Aakash, et al.
Publicado: (2021)

Management of the Adverse Effects of Immune Checkpoint Inhibitors
por: Morgado, Manuel, et al.
Publicado: (2020)

Immune Checkpoint Inhibitor Associated Hepatotoxicity in Primary Liver Cancer Versus Other Cancers: A Systematic Review and Meta‐Analysis
por: Fu, Jianyang, et al.
Publicado: (2021)

Corrigendum: Enteric Budesonide in Transplant and Native IgA Nephropathy: Real-World Clinical Practice
por: Lopez-Martinez, Marina, et al.
Publicado: (2023)

Mycophenolate mofetil for immune checkpoint inhibitor‐related hepatotoxicity relapsing during dose reduction of corticosteroid: A report of two cases and literature review
por: Ueno, Masayuki, et al.
Publicado: (2022)

Solubility Enhancement of Budesonide and Statistical Optimization of Coating Variables for Targeted Drug Delivery
por: Bhatt, Himanshu, et al.
Publicado: (2014)

Tumor DNA methylation profiles correlate with response to anti-PD-1 immune checkpoint inhibitor monotherapy in sarcoma patients
por: Starzer, Angelika M, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6nk5pem8mdqcgl4gma4etcbq86